Publication | Closed Access

Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial

InflammationPhase 1/2Cell TherapyTransplantationAutoimmune DiseaseMarrow TransplantationStem Cell TransplantationImmunologyAutoimmunityGraft SurvivalAllogeneic Stem-cell TransplantationInterleukin-6 InhibitionImmunotherapyMedicineCell TransplantationGraft Rejection